Following treatment, both Choi and Rim shared a strong interest in using machine learning to aid prevention, and together they founded Mediwhale to bring this to fruition. The diagnosis came too late, and Choi lost nearly 40 percent of his vision. Rim, a vitreoretinal surgeon, being treated for advanced glaucoma. Choi, a recent graduate student, was a patient of Dr. Mediwhale’s journey began in 2016 when the co-founders met under unfortunate circumstances. Early detection is key in averting a potentially irreversible health problem. Initial assessment by a family doctor can save patients both money and time, with wait times to see specialists often exceeding a month. A general practitioner can perform the retina image capture and if high disease risk is detected, the patient can be referred to a specialist for additional testing. Reti-Intelligence uses a simple fundus camera to capture images of the eye, and then within one minute the AI algorithm provides the disease risk assessment. Since its initial approvals, the algorithms have been further refined, with its deep learning based on over 500,000 global data sets and growing. Reti-CVD predicts future cardiovascular disease risk as accurately as a cardiac CT and Reti-CKD scans yield better risk prediction outcomes than traditional blood or urine tests. The accuracy and dependability of Reti-Intelligence already have resulted in approvals in Asia and Europe. Mediwhale is focused on cardiovascular (Reti-CVD) and kidney (Reti-CKD) health. The eye is the only organ in the body where blood vessels are directly seen without any invasive procedures. It leverages non-invasive retinal scans combined with extensively trained algorithms to diagnose disease conveniently for both patient and physician. “Our products are used right in the family doctor’s office, removing the need to visit a specialist or hospital and are easy to use for healthcare professionals.”Īccording to the news release, Reti-Intelligence uses deep learning algorithms to detect disease risks even before symptoms appear. “Our products are non-invasive, which means patients avoid both radiation risk from CT scans and the inconvenience and discomfort of blood tests,” he said in a news release. Choi, co-founder and CEO, the company was looking forward to bringing its products to the United States, as they represent an opportunity to provide affordable, accessible and accurate preventative care to improve the health of more than 300 million people. In November, Mediwhale presented at the American Heart Association (AHA) gathering in Chicago, the American Society of Nephrology’s (ASN) Kidney Week in Orlando, Florida, and the hospitals meeting with HeartX in Arkansas, a biotech accelerator to grow startups focused on cardiovascular innovation.Īccording to Kevin T. Leading up to its FDA approval process, Mediwhale presented findings from its Reti-Intelligence suite of diagnostics solutions that combine a simple scan of the eye’s retina with sophisticated AI to detect major health issues. conferences focused on cardiovascular and kidney health. South Korea-based Mediwhale made waves in the United States when its scientific teams spoke last week at three U.S.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |